The backend infrastructure built by compound pharmacies to serve telehealth giants like Hims and Ro is now mature. This creates an opportunity for new brands to quickly launch and ship prescription products, effectively using these pharmacies as a platform for regulated health and wellness DTC.

By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.

The personal genomics landscape is bifurcating. Direct-to-consumer companies offer broad, exploratory whole-genome sequencing for general interest, while clinician-mediated services provide targeted, actionable gene panels for specific medical conditions, creating distinct value propositions.

Two dominant strategies are winning. Companies can either be the absolute best at one specific thing (e.g., musculoskeletal care, women's health) or build a platform that aggregates these best-in-class solutions into a seamless 'digital front door' for insurers and corporations.

While digital advertising constitutes 75% of spend in the general economy, it's only about half that in healthcare. This lag, driven by an entrenched reliance on in-person sales reps, creates a long-term secular tailwind for platforms like Doximity as the industry inevitably shifts its marketing budget online.

Pharma companies now partner with telehealth providers to offer coupons that reduce the cost of the physician consultation itself. This marketing tactic incentivizes patients to seek a prescription for a specific drug, raising questions about overprescribing and conflicts of interest.

Direct-to-consumer telehealth companies like Hims achieve rapid growth via a vertically integrated model of marketing, medical groups, and pharmacies. This structure allows them to generate revenue from selling medicines, a more scalable business than relying on fees from the practice of medicine alone.

Despite the telehealth boom, 95% of ZocDoc's appointments for physical medicine are booked for in-person visits. The data suggests that while patients value the *option* of telehealth, they don't actually want it for somatic care, where a physical examination is crucial. The primary use case remains remote mental health services.

Telehealth platforms built on selling generic drugs face margin compression from price wars and high customer acquisition costs. Partnering to offer branded, in-demand medications provides a competitive advantage, creating a "gravitational pull" that attracts patients and builds a more defensible business model.